AI powered precision medicine for blood cancer
MyeloMap is a trusted platform that unifies patient records and applies AI to guide personalised therapy decisions and clinical trial options for relapsed and refractory myeloma.
About MyeloMap
MyeloMap is being developed by a team of clinicians, researchers and technologists committed to advancing precision medicine in blood cancer. Our goal is to make therapy decisions clearer and faster for patients with relapsed and refractory myeloma by combining the best of medical expertise with innovative AI.
We believe that by centralising patient data and applying predictive insights, we can support oncologists, healthcare providers and researchers in delivering better outcomes and opening new opportunities for care.
The Challenge in Myeloma Care
Patients with relapsed or refractory myeloma often have complex medical histories. Their records are scattered across different hospitals, and oncologists must make decisions with incomplete information. This slows down care and makes it harder to choose the best therapy with confidence.
What MyeloMap offers
A single platform that centralises patient data
All records in one place, removing the need to track information across hospitals.
AI summaries of history, tests and treatments
Quick, accurate overviews that save time and reduce complexity for clinicians.
Predictions of likely outcomes for different regimens
Data-driven insights to support more confident, personalised therapy choices.
Options to match patients to clinical trials
Helping clinicians identify new opportunities when standard treatments are limited.
Turning complex data into clear decisions
Industries We Serve
Oncologists
Confident, data-driven therapy decisions
Healthcare providers
More effective, efficient care pathways
Researchers
Access to complete data for patient cohort selection
Health systems
Trusted, centralised decision support
Help shape the future of precision medicine
MyeloMap is at an early stage. We are working with clinicians, healthcare providers and researchers to develop the platform. Register your interest to stay informed and be part of this journey.